Condition: Advanced Solid Tumor Cancer · Metastatic Solid Tumor · Sponsor: Eilean Therapeutics
ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor. This multicenter, open-label, first-in-human Phase 1 study will evaluate ZE94-0605 in adults with advanced, unresectable or metastatic solid tumors. Phase 1a will use sequential dose escalation to determine the maximally tolerated dose and biologically effective dose. Phase 1b will randomize participants with CCNE1 amplification, or another prospectively specified molecular feature, between two dose levels to select the recommended Phase 2 dose.
This description comes directly from the study's public registry record.
Ekaterina Dokukina · +1 858 353 4108 · kdokukina@eilenther.com
Always discuss trial participation with your own doctor first.
| St. George Private hospital | Kogarah, New South Wales, Australia | Recruiting |
| SOCRU - Southern Oncology Clinical Research Unit | Bedford Park, South Australia, Australia | Recruiting |
| Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology Uzbekistan | Tashkent, Uzbekistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07524140